Michael Gottlieb is a senior executive and board director, and is currently the President and CEO of EpiSwitch Rx.
Previously, Michael was Chief Commercial Officer of POINT Biopharma (PNT:NASDAQ). In this role, he was responsible for commercial operations and market strategy. As a founding member of the executive team, Michael led corporate development and planning, scientific and medical engagement and initially managed the clinical development programs.
Prior to joining POINT, Michael had various leadership roles at Sanofi Genzyme Canada, leading commercial operations, patient infusions and support programs, market access, pricing, strategy and finance across a product portfolio spanning immunology, neurology, oncology and rare diseases. Michael also served as the Rare Disease Franchise Head, with responsibility for sales and marketing in the large orphan drug, neuromuscular, and rare oncology business.
As a health care and pharmaceutical commercial leader, Michael brings a unique perspective on the scientific method with experience building leading edge laboratory and clinical research infrastructure and operations. Michael has also worked in public health care environments supporting hospitals in procurement, systems integration, and shared services with a focus on stakeholder accountability, value and strategic operations.
Michael has a strong record of governance, board leadership, strategic development, fundraising, financial stewardship, and corporate planning in public and private operations, supported by a foundation grounded in a professional accounting designation (CPA, CA). Michael has a bachelor of science in biology and a combined master's degree is business and accounting.